Tetanus

• CLINICAL_TRIALS withdrawal · 2025-06-05
  Clinical Trial Update: Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) [Phase 3]

  Phase 3 trial evaluating a pentavalent DTP-HB-Hib vaccine for immunogenicity and safety has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-12-26
  Clinical Trial Update: Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants [Phase 3]

  Phase 3 trial evaluating immunogenicity and safety of Infanrix-IPV/Hib (DTPa-IPV/Hib) in healthy Indian infants has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-10-09
  Clinical Trial Update: A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) [Phase 3]

  A Phase 3 study evaluating immunogenicity and safety of a whole-cell pertussis–containing vaccine given with Rotarix or RotaTeq has been wit…

• EMA withdrawal · 2014-01-07
  EMA Lapsed: Tritanrix HepB (Diphtheria toxoid;hepatitis B surface antigen;Bordetella pertussis (inactivated);tetanus toxoid) — GlaxoSmithKline Biologicals S.A.

  EMA status shows the Tritanrix HepB vaccine has lapsed and is no longer an active medicinal product in the EU.

• EMA withdrawal · 2013-08-23
  EMA Lapsed: Infanrix Penta (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain));hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.

  EMA status indicates Infanrix Penta is lapsed, with the product no longer active in this market.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2012-08-16
  EMA Withdrawn: Hexavac (purified diphtheria toxoid;purified tetanus toxoid;purified pertussis toxoid;purified pertussis filamentous haemagglutinin;hepatitis B surface antigen;Inactivated Type 1 Poliovirus (Mahoney);Inactivated Type 3 Poliovirus (Saukett);Haemophilus influenzae type b polysaccharide) — Sanofi Pasteur MSD, SNC

  The EMA has withdrawn Hexavac, a hexavalent combination vaccine, from the market. The decision was taken in 2012 and concerns multiple indic…

• EMA withdrawal · 2008-09-10
  EMA Withdrawn: Quintanrix (Diphtheria toxoid;tetanus toxoid;inactivated Bordetella pertussis;hepatitis B surface antigen (rDNA);Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.

  Quintanrix has been withdrawn from the market by GlaxoSmithKline Biologicals S.A., with the status indicating withdrawal for its diphtheria,…